Fund Holdings — Davern Capital Partners, LP

Total Portfolio Value:
$514.06M
Total Bought:
$514.06M
Total Sold:
$0
Net Transaction:
+$514.06M
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
BioNTech SEADS(BNTX)0682,148+682,148$0$67.06M13.04%+$67.06M
Royalty Pharma plcCL A(RPRX)0974,412+974,412$0$56.87M11.06%+$56.87M
Insmed Incorporated(INSM)0496,047+496,047$0$56.62M11.01%+$56.62M
Roivant Sciences Ltd.SHS(ROIV)01,472,808+1,472,808$0$53.86M10.48%+$53.86M
Ionis Pharmaceuticals, Inc.(IONS)01,087,142+1,087,142$0$48.54M9.44%+$48.54M
argenx SEADR(ARGX)037,597+37,597$0$36.05M7.01%+$36.05M
Regeneron Pharmaceuticals, Inc.(REGN)040,661+40,661$0$30.83M6.00%+$30.83M
Natera, Inc.(NTRA)063,200+63,200$0$26.12M5.08%+$26.12M
ABIVAX Société AnonymeADS(ABVX)0219,183+219,183$0$21.70M4.22%+$21.70M
Vera Therapeutics, Inc.CL A(VERA)0628,274+628,274$0$20.29M3.95%+$20.29M
Mineralys Therapeutics, Inc.(MLYS)0695,152+695,152$0$17.47M3.40%+$17.47M
Legend Biotech CorporationADS(LEGN)0828,880+828,880$0$16.49M3.21%+$16.49M
Arrowhead Pharmaceuticals, Inc.(ARWR)0229,300+229,300$0$15.01M2.92%+$15.01M
Eli Lilly and Company(LLY)012,600+12,600$0$14.58M2.84%+$14.58M
Generate Biomedicines, Inc.(GENB)0824,679+824,679$0$12.39M2.41%+$12.39M
Viridian Therapeutics, Inc.(VRDN)0560,710+560,710$0$11.55M2.25%+$11.55M
Avalo Therapeutics Inc0564,441+564,441$0$8.65M1.68%+$8.65M
Page 1 of 1